Skip to main content

Table 2 Total costs, life years gained (LYGs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER)

From: Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model

 

CAPD

HD

ICER/QALY

Costs

1,348,612,118

1,368,447,750

(34,723,527)

LYG

6.428

6.432

 

QALY

4.79

4.22

 
  1. ICER incremental cost-effectiveness ratio, LY = life years gained, QALY quality adjusted life years
  2. *Results are in discounted estimation. Costs are in Indonesian rupiah (IDR).One-way scenario-deterministic analysis showed that if we change several key input parameters in range 5–10% assumptions, the final ICER results indicate the good value for money for CAPD. The plots were scattered into two quadrants on CE plane, the scatter plot illustrates that as the incremental costs increased in accordance with the changes in incremental QALY (Fig. 1a), also particularly in cost saving CE plane area where there was also indicating the probability of CAPD as cost-saving, substantial QALY benefit with lower costs. Uncertainty deemed existed, particularly the wide range of the incremental QALY